Driven by sustained demand for interventional cardiology and neuromodulation devices, Boston Scientific (BSX) anticipates third-quarter 2025 revenue of roughly $4.97 billion, up 17–19 percent year on year. Adjusted earnings per share are guided between $0.70 and $0.72. For the full fiscal year, management projects revenue near $19.88 billion and EPS approaching $2.98. Strong procedure recovery in global hospitals and efficiency gains in manufacturing lifted gross margins. Analysts note that upcoming launches in mapping systems and structural-heart therapies could extend growth into FY26, although logistics costs and currency movements remain watch factors.